Susan H. Alexander
Net Worth

Last updated:

What is Susan H. Alexander net worth?

The estimated net worth of Ms. Susan H. Alexander is at least $60,641,461 as of 16 Feb 2024. She owns shares worth $5,466,195 as insider, has earned $26,735,266 from insider trading and has received compensation worth at least $28,440,000 in Biogen Inc..

What is the salary of Susan H. Alexander?

Ms. Susan H. Alexander salary is $1,580,000 per year as Executive Vice President, Chief Legal Officer & Sec. in Biogen Inc..

How old is Susan H. Alexander?

Ms. Susan H. Alexander is 68 years old, born in 1957.

What stocks does Susan H. Alexander currently own?

As insider, Ms. Susan H. Alexander owns shares in one company:

Company Title Shares Price per share Total value
Biogen Inc. (BIIB) Executive Vice President, Chief Legal Officer & Sec. 39,396 $138.75 $5,466,195

What does Biogen Inc. do?

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

BIIB logo
BIIB
Biogen Inc.
$138.75

Susan H. Alexander insider trading

Biogen Inc.

Ms. Susan H. Alexander has made 16 insider trades between 2007-2024, according to the Form 4 filled with the SEC.

The largest trade she's ever made was exercising 58,070 units of BIIB stock on 27 Jul 2012. As of 16 Feb 2024 she still owns at least 39,396 units of BIIB stock.

Transaction Date Security Shares Price per share Total value Source
Option
Restricted Stock Unit 1,614 N/A N/A
Option
Common Stock 3,423 N/A N/A
Option
Performance Stock Unit 3,423 N/A N/A
Option
Common Stock 1,614 N/A N/A
Option
Common Stock 2,575 N/A N/A
Option
Restricted Stock Unit 2,575 N/A N/A
Option
Restricted Stock Unit 2,190 N/A N/A
Option
Common Stock 2,190 N/A N/A
Option
Common Stock 1,920 N/A N/A
Option
Restricted Stock Unit 1,920 N/A N/A
Option
Restricted Stock Unit 2,575 N/A N/A
Option
Common Stock 1,448 N/A N/A
Option
Common Stock 2,575 N/A N/A
Option
Restricted Stock Unit 1,448 N/A N/A
Sale
Common Stock 5,532 $280.7 $1,552,832
Option
Restricted Stock Unit 1,485 N/A N/A
Option
Common Stock 1,485 N/A N/A
Option
Restricted Stock Unit 1,154 N/A N/A
Option
Common Stock 1,126 N/A N/A
Option
Restricted Stock Unit 1,126 N/A N/A
Option
Common Stock 1,154 N/A N/A
Option
Restricted Stock Unit 4,355 N/A N/A
Option
Common Stock 2,769 N/A N/A
Option
Restricted Stock Unit 1,553 N/A N/A
Option
Common Stock 1,553 N/A N/A
Option
Common Stock 5,967 N/A N/A
Option
Restricted Stock Unit 5,967 N/A N/A
Option
Stock Option (Right to Buy) 6,395 $48.52 $310,285
Option
Common Stock 8,058 $24.26 $195,487
Option
Restricted Stock Unit 1,663 N/A N/A
Option
Restricted Stock Unit 1,685 N/A N/A
Option
Common Stock 1,685 N/A N/A
Option
Restricted Stock Unit 3,268 N/A N/A
Option
Common Stock 3,268 N/A N/A
Option
Restricted Stock Unit 857 N/A N/A
Option
Common Stock 857 N/A N/A
Option
Restricted Stock Unit 1,635 N/A N/A
Option
Common Stock 1,635 N/A N/A
Option
Restricted Stock Unit 1,712 N/A N/A
Option
Common Stock 1,712 N/A N/A
Sale
Common Stock 4,974 $290.01 $1,442,510
Sale
Common Stock 7,758 $285 $2,211,030
Option
Restricted Stock Unit 5,559 N/A N/A
Option
Common Stock 5,559 N/A N/A
Option
Restricted Stock Unit 636 N/A N/A
Option
Common Stock 636 N/A N/A
Option
Common Stock 3,289 N/A N/A
Option
Restricted Stock Unit 3,289 N/A N/A
Option
Common Stock 2,498 N/A N/A
Option
Restricted Stock Unit 2,498 N/A N/A
Option
Restricted Stock Unit 1,627 N/A N/A
Option
Restricted Stock Unit 3,769 N/A N/A
Option
Common Stock 1,627 N/A N/A
Option
Common Stock 3,769 N/A N/A
Option
Restricted Stock Unit 3,909 N/A N/A
Option
Common Stock 3,909 N/A N/A
Option
Common Stock 2,498 N/A N/A
Option
Restricted Stock Unit 2,498 N/A N/A
Option
Common Stock 3,821 N/A N/A
Option
Restricted Stock Unit 3,821 N/A N/A
Option
Common Stock 2,142 N/A N/A
Option
Restricted Stock Unit 2,142 N/A N/A
Option
Restricted Stock Unit 3,909 N/A N/A
Option
Common Stock 3,909 N/A N/A
Option
Restricted Stock Unit 2,498 N/A N/A
Option
Common Stock 2,498 N/A N/A
Option
Common Stock 3,821 N/A N/A
Option
Restricted Stock Unit 3,821 N/A N/A
Option
Restricted Stock Unit 3,909 N/A N/A
Option
Common Stock 3,909 N/A N/A
Option
Common Stock 2,165 N/A N/A
Option
Restricted Stock Unit 2,165 N/A N/A
Sale
Common Stock 1,165 $142.99 $166,583
Option
Stock Option (Right to Buy) 58,070 $55.11 $3,199,947
Sale
Common Stock 58,070 $150 $8,710,500
Option
Common Stock 58,070 $55.11 $3,199,947
Option
Common Stock 49,800 $47.52 $2,366,247
Option
Stock Option (Right to Buy) 20,000 $45.72 $914,400
Sale
Common Stock 49,800 $140 $6,972,000
Option
Stock Option (Right to Buy) 20,000 $44.73 $894,600
Sale
Common Stock 20,000 $44.73 $894,600
Option
Common Stock 20,000 $44.73 $894,600
Option
Common Stock 16,764 $44.73 $749,854
Option
Stock Option (Right to Buy) 16,764 $44.73 $749,854
Sale
Common Stock 16,764 $44.73 $749,854
Sale
Common Stock 3,236 $44.73 $144,746
Option
Stock Option (Right to Buy) 3,236 $44.73 $144,746
Option
Common Stock 3,236 $44.73 $144,746
Sale
Common Stock 4,255 $115.43 $491,155
Sale
Common Stock 2,145 $115.53 $247,812
Option
Common Stock 3,822 N/A N/A
Option
Restricted Stock Unit 3,822 N/A N/A
Sale
Common Stock 2,842 $118.01 $335,384
Option
Restricted Stock Unit 3,911 N/A N/A
Option
Common Stock 3,911 N/A N/A
Sale
Common Stock 1,165 $102.04 $118,877
Sale
Common Stock 20,993 $97.24 $2,041,443
Option
Restricted Stock Unit 3,144 N/A N/A
Option
Common Stock 3,144 N/A N/A
Option
Common Stock 2,666 N/A N/A
Option
Restricted Stock Unit 2,666 N/A N/A
Option
Restricted Stock Unit 3,333 N/A N/A
Option
Common Stock 3,333 N/A N/A
Sale
Common Stock 2,000 $70 $140,000
Sale
Common Stock 8,599 $60 $515,940
Option
Restricted Stock Unit 2,667 N/A N/A
Option
Common Stock 2,667 N/A N/A
Option
Restricted Stock Unit 3,333 N/A N/A
Option
Common Stock 3,333 N/A N/A
Option
Common Stock 2,667 N/A N/A
Option
Common Stock 3,334 N/A N/A

Biogen key executives

Biogen Inc. executives and other stock owners filed with the SEC: